Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis - Klempner, Samuel J.; Maron, Steven B.; Chase, Leah; Lomnicki, Samantha; Wainberg, Zev A.; Catenacci, Daniel V.T. (The oncologist (Dayton, Ohio), 2019)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - administration & dosage; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophagogastric Junction - drug effects; Esophagogastric Junction - pathology; Female; Fluorouracil - administration & dosage; FOLFIRI; Follow-Up Studies; Gastric cancer; Gastrointestinal Cancer; GEJ adenocarcinoma; Humans; Leucovorin - administration & dosage; Male; Middle Aged; Paclitaxel - administration & dosage; Prognosis; Ramucirumab; Retrospective Studies; Second line; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Survival Rate; Second line; Ramucirumab; GEJ adenocarcinoma; Gastric cancer; FOLFIRI